<DOC>
	<DOCNO>NCT02381509</DOCNO>
	<brief_summary>PRESERVE multi-center , prospective , open-label , non-randomized investigation commercially available IVC filter 6 manufacturer place subject prevention pulmonary embolism ( PE ) . This study enroll approximately 1,800 IVC filter subject 60 site US . All treat subject evaluated procedure , 3-months , 6-months ( phone ) , 12-months , 18-months ( phone ) , 24-months post-procedure . The primary objective investigational device exemption ( IDE ) clinical investigation evaluate safety effectiveness commercially available IVC filter ( retrievable permanent ) subject clinical need mechanical prophylaxis PE IVC filter .</brief_summary>
	<brief_title>Predicting Safety Effectiveness Inferior Vena Cava Filters</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<criteria>Male Female , age 18 year old ; Requires IVC filter prevention pulmonary embolism ( PE ) ; Provide write informed consent write HIPAA authorization prior initiation study procedure ; Willing comply specify followup Subject unable participate study evaluation pre posttreatment Known sensitivity contrast serious contrast reaction anaphylaxis premedication know unsuccessful alleviating symptom</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>inferior vena cava filter</keyword>
</DOC>